Literature DB >> 6523433

Pharmacokinetics and anticoagulant effect of hirudin in man.

F Markwardt, G Nowak, J Stürzebecher, U Griessbach, P Walsmann, G Vogel.   

Abstract

The pharmacokinetics and the effects on the haemostatic system of hirudin were assessed in six healthy subjects after single intravenous or subcutaneous dose (1000 AT-U/kg). When hirudin was given intravenously first-order elimination kinetics followed the initial distribution phase. The decline in plasma hirudin concentration was most adequately expressed by a biexponential equation describing a two compartment model. A mean elimination half-life of 0.84 hr and a mean volume of distribution of 12.9 l were calculated. After subcutaneous injection a low hirudin level (approximately 0.5 AT-U/ml) was maintained for a prolonged period of time. In the 24 hour-urine up to 50 per cent of the administered amount of hirudin was excreted in active form. Thrombin time, partial thromboplastin time and prothrombin time measured in plasma samples ex vivo were prolonged dependent on the hirudin plasma level. Platelet counts, fibrinogen level and the fibrinolytic system were unchanged. Bleeding time was prolonged twice at maximum. Subcutaneous or intravenous administration of pure hirudin was tolerated without side-effects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6523433

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

1.  Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 2.  Small bite, large impact-saliva and salivary molecules in the medicinal leech, Hirudo medicinalis.

Authors:  Jan-Peter Hildebrandt; Sarah Lemke
Journal:  Naturwissenschaften       Date:  2011-11-09

Review 3.  Hirudin, a new therapeutic tool?

Authors:  J Bichler; H Fritz
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

4.  Amelioration of collagen-induced arthritis by thrombin inhibition.

Authors:  I Marty; V Péclat; G Kirdaite; R Salvi; A So; N Busso
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

5.  Catabolism of hirudin and thrombin-hirudin complexes in the rat.

Authors:  J Bichler; J W Baynes; S R Thorpe
Journal:  Biochem J       Date:  1993-12-15       Impact factor: 3.857

6.  Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration.

Authors:  J M Cardot; G Y Lefèvre; J A Godbillon
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

7.  Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin.

Authors:  J Féthière; Y Tsuda; R Coulombe; Y Konishi; M Cygler
Journal:  Protein Sci       Date:  1996-06       Impact factor: 6.725

Review 8.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

9.  Direct Comparison of Aspirin Plus Hirudin, Aspirin Plus Heparin, and Aspirin Alone Among 12,000 Patients with Acute Myocardial Infarction Not Receiving Thrombolysis: Rationale and Design of the First American Study of Infarct Survival (ASIS-1).

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 10.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.